ImmunityBio is a biotechnology company developing next-generation immunotherapies to activate the immune system against cancer and infectious diseases by harnessing both adaptive and innate immune responses. The company's core platform, Cancer BioShield, comprises multiple therapeutic modalities including cytokine fusion proteins, vaccine vectors, engineered NK cell therapies, and immunomodulators; its lead approved product is ANKTIVA, a first-in-class IL-15 superagonist antibody-cytokine fusion protein for treating bladder cancer and lung cancer across multiple jurisdictions. ImmunityBio generates revenue from commercial sales of approved therapies and builds a broad pipeline spanning solid tumors, liquid tumors, and infectious diseases, supported by partnerships with academic institutions and pharmaceutical companies, while maintaining vertically integrated manufacturing capability for its therapeutic modalities.